Physician profile
Alak Ray
NPI 1700891009
$2,293.22
in general payments reported to CMS, 2019-2025
15 companies · $266 in 2025
The $266 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $320 · 2021: $244 · 2022: $434 · 2023: $319 · 2024: $367 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $951.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $763.22 | 2019-2024 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $362.56 | 2022-2025 | |
| Horizon Therapeutics Plc | $261.98 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $196.21 | 2019-2025 | Farxiga, Lokelma |
| Ardelyx, INC. | $183.12 | 2023-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $162.20 | 2022-2023 | Benlysta |
| Akebia Therapeutics INC | $95.55 | 2019-2024 | Auryxia, Vafseo |
| Novo Nordisk INC | $58.51 | 2024-2025 | Rybelsus, Ozempic |
| Amgen INC. | $49.26 | 2024 | Tavneos, Krystexxa |
| Aurinia Pharma U.S., INC. | $44.93 | 2024 | Lupkynis |
| Lilly USA, LLC | $26.74 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $23.43 | 2022 | |
| Calliditas Therapeutics US INC. | $22.78 | 2023 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.90 | 2023 | Jardiance |
| Mallinckrodt Hospital Products INC. | $20.83 | 2024 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alak Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.